No Data
KEYTRUDA (Pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Express News | Keytruda® (Pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (Tnbc)
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Express News | Merck & Co Inc - Keytruda Reduces Risk of Death by 29% in Advanced Melanoma
Express News | Ten-Year Data for Merck’s Keytruda® (Pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Ten-Year Data for Merck's KEYTRUDA (Pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma